ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
2.820
-0.130 (-4.41%)
Oct 31, 2024, 4:00 PM EDT - Market closed
ADC Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 66.75 | 69.56 | 209.91 | 33.92 | - | 2.34 | Upgrade
|
| Revenue Growth (YoY) | -63.80% | -66.86% | 518.89% | - | - | 105.26% | Upgrade
|
| Cost of Revenue | 112.59 | 129.66 | 189.76 | 159.4 | 141.82 | 107.54 | Upgrade
|
| Gross Profit | -45.85 | -60.1 | 20.15 | -125.48 | -141.82 | -105.2 | Upgrade
|
| Selling, General & Admin | 92.94 | 105.89 | 143.49 | 136.24 | 77.23 | 14.2 | Upgrade
|
| Operating Expenses | 92.94 | 105.89 | 143.49 | 136.24 | 77.23 | 14.2 | Upgrade
|
| Operating Income | -138.78 | -165.99 | -123.34 | -261.72 | -219.05 | -119.4 | Upgrade
|
| Interest Expense | -50.9 | -46.33 | -36.73 | -18.34 | -4.93 | -0.16 | Upgrade
|
| Interest & Investment Income | 12.19 | 10.54 | 2.57 | 0.07 | 0.83 | 2.25 | Upgrade
|
| Earnings From Equity Investments | -4.68 | -5.53 | -10.08 | -6.67 | 24.37 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.11 | -0.05 | -0.11 | 0.05 | -0.58 | -0.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.86 | 6.4 | 52.91 | 35.11 | -46.4 | 1.66 | Upgrade
|
| EBT Excluding Unusual Items | -171.42 | -200.95 | -114.79 | -251.51 | -245.75 | -115.9 | Upgrade
|
| Asset Writedown | - | - | - | - | -0.22 | - | Upgrade
|
| Other Unusual Items | - | - | -42.11 | - | - | - | Upgrade
|
| Pretax Income | -171.42 | -200.95 | -156.9 | -251.51 | -245.96 | -115.9 | Upgrade
|
| Income Tax Expense | 43.48 | 39.11 | 0.23 | -21.48 | 0.33 | 0.58 | Upgrade
|
| Net Income | -214.91 | -240.05 | -157.13 | -230.03 | -246.29 | -116.48 | Upgrade
|
| Net Income to Common | -214.91 | -240.05 | -157.13 | -230.03 | -246.29 | -116.48 | Upgrade
|
| Shares Outstanding (Basic) | 86 | 82 | 78 | 77 | 65 | 49 | Upgrade
|
| Shares Outstanding (Diluted) | 86 | 82 | 78 | 77 | 65 | 49 | Upgrade
|
| Shares Change (YoY) | 6.74% | 4.55% | 1.83% | 17.33% | 32.73% | 5.75% | Upgrade
|
| EPS (Basic) | -2.51 | -2.94 | -2.01 | -3.00 | -3.77 | -2.36 | Upgrade
|
| EPS (Diluted) | -2.51 | -2.94 | -2.01 | -3.00 | -3.77 | -2.36 | Upgrade
|
| Free Cash Flow | -146.8 | -121.9 | -139 | -236.81 | -169.53 | -121.94 | Upgrade
|
| Free Cash Flow Per Share | -1.71 | -1.49 | -1.78 | -3.09 | -2.59 | -2.47 | Upgrade
|
| Gross Margin | -68.69% | -86.40% | 9.60% | - | - | - | Upgrade
|
| Operating Margin | -207.92% | -238.63% | -58.76% | -771.65% | - | -5102.52% | Upgrade
|
| Profit Margin | -321.98% | -345.11% | -74.86% | -678.20% | - | -4977.95% | Upgrade
|
| Free Cash Flow Margin | -219.93% | -175.25% | -66.22% | -698.20% | - | -5211.07% | Upgrade
|
| EBITDA | -137.47 | -164.8 | -122.28 | -260.75 | -218.23 | -118.82 | Upgrade
|
| EBITDA Margin | -205.96% | -236.92% | -58.26% | - | - | - | Upgrade
|
| D&A For EBITDA | 1.31 | 1.19 | 1.06 | 0.97 | 0.82 | 0.58 | Upgrade
|
| EBIT | -138.78 | -165.99 | -123.34 | -261.72 | -219.05 | -119.4 | Upgrade
|
| EBIT Margin | -207.92% | -238.63% | -58.76% | - | - | - | Upgrade
|
| Revenue as Reported | 66.75 | 69.56 | 209.91 | 33.92 | - | 2.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.